Medline Inc. heads into the week of May 14 with shorts rebuilding, analysts trimming targets, and the stock nursing its worst two-week stretch since listing.
The clearest story this week is in short positioning. Short interest climbed to 6.7% of the free float on May 12 — up from 5.5% at the start of the week and the highest reading since late April. The week-on-week build of nearly 16% in share terms marks the sharpest single-week increase in the tracked series. That follows a sharp unwind through late April, when SI had pulled back from above 8% in early April. The borrow market, however, offers little confirmation of urgency. Cost to borrow remains negligible at around 0.53% — barely changed over the past month — and borrow availability is well into normal territory, with roughly 24% of the pool now deployed. Neither metric signals a crowded or constrained short trade. The rebuild looks deliberate rather than desperate.
Options traders are running slightly more defensive than their recent average. The put/call ratio is at 0.53, above its 20-day mean of 0.46 by about 0.75 standard deviations — a modest tilt toward protection, not a panic. The PCR has drifted higher over the past three weeks from a reading near 0.21 in mid-April, coinciding almost exactly with the stock's deterioration. The 52-week high on the PCR sits at 1.97, so the current reading is nowhere near an extreme — but the directional shift is worth noting.
The catalyst for all of this was the Q1 earnings print. MDLN fell 7.6% on May 6 after reporting, and shed a further 6.2% on May 8 — a back-to-back loss that took the stock from near $45 to $38.55. The month-on-month price decline is now 15.5%, and the year-to-date drawdown stands at 8.2%. The post-earnings selling has compressed the PE multiple by more than six points over 30 days to 24.7x, and the price-to-book has contracted by over 0.5 turns to 1.94x. The EV/EBITDA of 14.2x has barely moved, suggesting the market is largely repricing the equity rather than reassessing the fundamental enterprise value story.
The Street's response to the print has been to trim rather than walk away. Citigroup cut its target from $60 to $55 on May 7 while maintaining a Buy. Bernstein nudged lower from $56 to $54, also holding at Outperform. The consensus mean target now sits near $52, implying roughly 35% upside from current levels — a gap that has widened sharply as the stock fell but which reflects a Wall Street still broadly constructive on the name. Tigress Financial, notably, raised its target to $62 on May 13, bucking the trend. The bull case rests on Medline's entrenched position with major US health systems, its supply chain scale, and the long runway for Prime Vendor penetration. The bear case is more structural: Prime Vendor relationships still account for only around 35% of total sales, and Medline remains heavily US-concentrated in a sector where competitive pressure is intensifying.
Ownership adds a layer of overhang worth watching. The March 10 secondary saw major PE holders — Carlyle and Hellman & Friedman — collectively trim billions of dollars of stock at around $40–$41 per share. Carlyle still holds 22% of shares outstanding. Blackstone trimmed nearly 18.7 million shares in the same quarter, reducing its stake to around 15%. With the stock now trading below that secondary price, further supply from the PE overhang will be a recurring concern for the register as lockup dynamics evolve. The short score at 51.4 — climbing from 46 a week ago — captures this combination of rising short interest and negative price momentum without yet reaching elevated territory.
The RSI at 29.5 places the stock in deeply oversold territory. The next confirmed earnings event is June 11. Between now and then, the debate is less about Medline's long-term positioning and more about whether the PE-holder overhang clears and whether shorts — who are rebuilding at a brisk pace into the post-earnings dip — find further reasons to press.
See the live data behind this article on ORTEX.
Open MDLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
